Tvardi Therapeutics (TVRD) Total Current Liabilities (2013 - 2026)

Tvardi Therapeutics has reported Total Current Liabilities for 14 years, with the latest figure at $11.3 million in Q1 2026.

• Quarterly Total Current Liabilities rose 838.95% year-over-year to $11.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.3 million (up 838.95% YoY) and the FY2025 annual result came in at $11.0 million, up 6.51% from the prior year.
• Total Current Liabilities rose to $11.3 million in Q1 2026 per TVRD's latest filing, from $11.0 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $28.2 million in Q3 2022 and troughed at $1.2 million in Q1 2025.
• A 5-year average of $16.3 million and a median of $15.1 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2025 and 2026: Total Current Liabilities slumped 92.06% in 2025, then surged 838.95% in 2026.
• Over 5 years, Total Current Liabilities stood at $23.5 million in 2022, then climbed by 9.1% to $25.6 million in 2023, then sank by 59.49% to $10.4 million in 2024, then climbed by 6.51% to $11.0 million in 2025, then gained by 1.96% to $11.3 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $11.3 million, $11.0 million, and $11.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.